Rocket Pharmaceuticals(US:RCKT) Prnewswireยท2025-06-15 14:40Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses [2][4][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Rocket Pharmaceuticals - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. - It was revealed that Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which contributed to artificially inflated stock prices [4]. - Following the announcement of a clinical hold by the FDA due to a Serious Adverse Event, including a patient death, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [5][6]. Group 3: Investor Communication and Whistleblower Encouragement - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Rocket's conduct [8].